The Fort Worth home for pharmaceutical giant Galderma’s stateside headquarters has announced a new group of executives as the company readies the launch of several products over the next few months.
The North American headquarters has seen much turnover in recent years. In 2013, the company introduced its rosacea treatment drug Mirvaso. Some patients complained of side effects that made redness on their face even worse than before they began taking the treatment. Weeks later, Francois Fournier stepped down as its North Texas president, a post he held since June 2009. Two months after that, the company announced layoffs.
Stuart Raetzman was named president in March 2014, but has since taken a job heading the Swiss company’s operations in Lausanne, Switzerland as global chief executive officer. Todd Zavodnick, a former vice president and general manager of the company’s Aesthetic and Corrective unit, will now be the U.S. president.
Under Raetzman, the company split off into three business units: Self-Medication, which includes over-the-counter drugs such as the heavyweight Cetaphil; Aesthetic and Corrective, drugs that aid lip enhancement and treat lines around the mouth in patients older than 21; and Prescription, which includes anything the company produces that requires a doctor’s approval. The controversial Mirvaso falls under that.
Zavodnick oversaw the Aesthetic and Corrective business. He has worked across the world (Asia, Europe, Middle East, Africa, and Latin America) for Galderma and Alcon Laboratories, the Fort Worth eye care pharmaceutical company. He will continue to head the Aesthetic and Corrective unit until a successor is named.
“With this reorganization, our customers will see that all the reasons they value and trust Galderma will remain unchanged, while our ambitions and product lines are growing simultaneously in three business channels to meet even greater skin health needs,” Zavodnick said in a statement.
The company recently won FDA approval for Restylane Silk, the first drug to get federal approval to help ease lip lines. In January, the company launched a new over-the-counter acne regimen named Benzac. Galderma promises additional products will hit the market later this year.
Below are the new executives:
Safia Rizvi is Vice President and General Manager of U.S. Prescription Business Unit. She was formally the Managing Director and General Manager of UCB Pharmaceuticals in Mumbai, India.
Miles Harrison has been named Vice President and General Manager U.S. Self-Medication Business. Harrison joined Galderma from Novartis.
Dr. Philip Brown MD, JD, continues to serve as Senior Vice President of Medical and Regulatory Affairs.